Stephen Garbacz

Corporate Officer/Principal presso Tessera Therapeutics, Inc.

65 anni

Health Technology

Consumer Services

Profilo

Stephen Garbacz is currently the Head of Finance at Tessera Therapeutics, Inc. He previously worked as the CAO and Executive Director of Finance at Epizyme, Inc. in 2012.
From 2019 to 2021, he was the Vice President of Finance and Corporate Controller at Anika Therapeutics, Inc. Prior to that, he was the Senior Vice President of Finance and Operations at Spero Therapeutics, Inc. Mr. Garbacz received his undergraduate degree from George Mason University and his MBA from The Leonard N Stern School of Business.

Posizioni attive di Stephen Garbacz

Società	Posizione	Inizio
Tessera Therapeutics, Inc. Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA.	Corporate Officer/Principal	01/05/2021

Tutte le posizioni attive di Stephen Garbacz

Precedenti posizioni note di Stephen Garbacz

Società	Posizione	Fine
ANIKA THERAPEUTICS, INC.	Comptroller/Controller/Auditor	01/05/2021
SPERO THERAPEUTICS, INC.	Direttore operativo	-
EPIZYME, INC.	Direttore Finanziario/CFO	-

Vedi nel dettaglio l'esperienza di Stephen Garbacz

Formazione di Stephen Garbacz

The Leonard N Stern School of Business	Masters Business Admin
George Mason University	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Stephen Garbacz

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	2
SPERO THERAPEUTICS, INC.	Health Technology
ANIKA THERAPEUTICS, INC.	Health Technology

Aziende private	2
Epizyme, Inc. Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.	Health Technology
Tessera Therapeutics, Inc. Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA.	Health Technology